Cytosorbents Corporation (CTSO)

Market Cap	45.64M
Revenue (ttm)	36.35M
Net Income (ttm)	-28.51M
Shares Out	54.29M
EPS (ttm)	-0.64
PE Ratio	n/a
Forward PE	7.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	105,212
Open	0.832
Previous Close	0.810
Day's Range	0.810 - 0.864
52-Week Range	0.782 - 4.290
Beta	0.59
Analysts	Buy
Price Target	2.50 (+197.37%)
Earnings Date	May 9, 2024

About CTSO

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1997
• Employees: 186
• Stock Exchange: NASDAQ
• Ticker Symbol: CTSO

Financial Performance

In 2023, Cytosorbents's revenue was $36.35 million, an increase of 4.79% compared to the previous year's $34.69 million. Losses were -$28.51 million, -13.12% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for CTSO stock is "Buy." The 12-month stock price forecast is $2.5, which is an increase of 197.37% from the latest price.

Price Target

$2.5

(197.37% upside)

Analyst Consensus: Buy